As monkeypox continues to pose a public health challenge globally, vaccination remains a pivotal strategy for controlling its spread and preventing severe disease. The primary vaccine used in many countries, including the United States, Canada, and Europe, is the JYNNEOS vaccine— a non-replicating Modified Vaccinia Ankara (MVA) vaccine designed to protect against both monkeypox and smallpox.
Vaccine Use and Recommendations
JYNNEOS is administered as a two-dose series, given 28 days apart, and is currently the preferred vaccine due to its favorable safety profile compared to older, replicating smallpox vaccines like ACAM2000. This vaccine is recommended primarily for adults aged 18 and older who are at increased risk of monkeypox infection, including certain occupational groups such as laboratory personnel handling the virus and people with specific behavioral risk factors.
Vaccination can be given both pre-exposure, to reduce the risk of infection, and post-exposure, to lessen the likelihood of developing symptoms or severe disease. Ideally, people recently exposed to monkeypox should receive the vaccine within four days of exposure; although vaccination up to 14 days after exposure may still provide benefits if symptoms have not started.
Effectiveness and Safety
JYNNEOS offers protection against both clade I and clade II monkeypox viruses, the two main variants responsible for outbreaks. The vaccine’s two-dose regimen is essential to achieve optimal protection, with the second dose ideally given four weeks after the first. While some have questioned the need for additional booster doses, current recommendations advise against administering more than the standard two doses unless new evidence emerges. Individuals who have recovered from monkeypox generally are not advised to receive the vaccine, as reinfection is very rare and typically less severe when it occurs.
Alternatives and Treatments
Where JYNNEOS is unavailable or contraindicated, the older ACAM2000 vaccine remains an option in some jurisdictions despite a higher risk of adverse effects, including myocarditis and progressive vaccinia in immunocompromised individuals. Japan uses the LC16 smallpox vaccine, which has a long-standing safety record. Beyond vaccination, tecovirimat (TPOXX) is the leading antiviral treatment authorized in several countries for monkeypox, though recent trials suggest its benefit is greatest when used early in severe cases rather than routine mild infections. Supportive care including pain management, hydration, and prevention of secondary bacterial infections remains fundamental to patient management.
Public Health Approach and Access
The World Health Organization advises prioritizing vaccine allocation to persons at highest risk, including those living with immunocompromising conditions, pregnant women, and young children, especially in regions with ongoing transmission. Mass vaccination campaigns are not currently recommended given vaccine supply constraints and epidemiological factors. Vaccination efforts focus on outbreak containment and protecting vulnerable groups.
Health authorities in various countries encourage eligible individuals to seek vaccination through healthcare providers, pharmacies, or public health clinics. Insurance coverage is generally available for the JYNNEOS vaccine under most plans in the U.S. and Canada, though some regions may have local differences affecting accessibility.
Implications for Public Health
Monkeypox vaccination is a key preventive tool that complements behavioral interventions like avoiding close physical contact with symptomatic individuals to reduce transmission risks. Continued surveillance, vaccine uptake among at-risk populations, and timely administration are critical to controlling monkeypox outbreaks and minimizing severe outcomes. These vaccination efforts, combined with evidence-based treatment protocols, bolster the global response to this emerging infectious disease threat.
For authoritative guidance, healthcare providers and the public can refer to the World Health Organization’s resources on monkeypox vaccination and recommendations from the U.S. Centers for Disease Control and Prevention.
Read more on Globally Pulse Health.
